{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:52:10Z","timestamp":1790275930968,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T00:00:00Z","timestamp":1462233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2016,7,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Older adults with relapsed\/refractory B\u2010precursor acute lymphoblastic leukemia (r\/r ALL) are reported to have a poor prognosis and few therapeutic options. In the current study, the authors evaluated treatment with single\u2010agent blinatumomab in adults aged \u226565 years with r\/r ALL.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A total of 261 adults with r\/r ALL who were examined across two phase 2 studies received blinatumomab in cycles of 4\u2010week continuous infusion and 2\u2010week treatment\u2010free intervals. The primary endpoint in each study was complete remission (CR) or CR with partial hematologic recovery (CRh) during the first 2 cycles. Data were pooled and analyzed according to patient age at screening (aged \u226565 years vs aged &lt;65 years).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of 36 older adults, 56% (95% confidence interval [95% CI], 38%\u201072%) achieved CR\/CRh during the first 2 cycles compared with 46% (225 patients) (95% CI, 40%\u201053%) of younger adults. Complete minimal residual disease responses were 60% in older and 70% in younger responders. Three older responders (15%) and 61 younger responders (59%) proceeded to allogeneic hematopoietic stem cell transplantation. Kaplan\u2010Meier curves overlapped for relapse\u2010free and overall survival for both age groups. Older adults were found to have a similar incidence of grade \u22653 adverse events (AEs) as younger adults (86% vs 80%) but more grade \u22653 neurologic events (28% vs 13%). Cytokine release syndrome occurred in 7 older (19%) (1 case of grade 3) and 23 younger (10%) (4 cases of grade \u22653) adults. There were no treatment\u2010related fatal AEs reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Older adults with r\/r ALL who were treated with single\u2010agent blinatumomab were found to have similar hematologic response rates and incidence of grade \u22653 AEs compared with younger adults but had more neurologic events, which were reversible and primarily resolved with treatment interruption. <jats:bold><jats:italic>Cancer<\/jats:italic> 2016;122:2178\u201385<\/jats:bold>. \u00a9 <jats:italic>2016 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30031","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T10:03:34Z","timestamp":1462356214000},"page":"2178-2185","source":"Crossref","is-referenced-by-count":86,"title":["Blinatumomab treatment of older adults with relapsed\/refractory B\u2010precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies"],"prefix":"10.1002","volume":"122","author":[{"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"Gehr Leukemia Center City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf C.","family":"Bargou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology\/Oncology, Comprehensive Cancer Center Mainfranken University Hospital of W\u00fcrzburg Wurzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Grande Garcia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology, University Hospital \u201c12 de Octubre\u201d Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology University of Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Muenster Muenster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"Department of Medicine II University Hospital Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research Munich GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Amgen Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Amgen Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Jia","sequence":"additional","affiliation":[{"name":"Amgen South San Francisco South San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[{"name":"Medical Clinic and Polyclinic II University Hospital of W\u00fcrzburg Wurzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e343"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09095.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-379016"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-551937"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"issue":"4","key":"e_1_2_8_9_1","first-page":"S28","article-title":"Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)","volume":"11","author":"Weiss MA","year":"1997","journal-title":"Leukemia."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_8_13_1","volume-title":"NCI Common Terminology Criteria for Adverse Events (CTCAE)","author":"National Cancer Institute","year":"2014"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.364"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.53"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12561"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00778.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.863"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23819"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.131"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.6193"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-264077"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-266551"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.140"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.1203"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30031","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:09:11Z","timestamp":1760288951000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,3]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,7,15]]}},"alternative-id":["10.1002\/cncr.30031"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30031","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,3]]}}}